Fangda advised Swire Group in acquiring the controlling shares of DeltaHealth

Fangda advised Swire Group in acquiring the controlling shares of DeltaHealth China Limited (“DeltaHealth”) from Eight Roads.

DeltaHealth specializes in cardiovascular services and operates a private hospital focusing on the treatment of cardiovascular diseases (“Shanghai Delta Hospital”), and also a clinic in Shanghai. In 2023, Shanghai Delta Hospital ranked first among all private hospitals in Shanghai for the number of cardiovascular surgeries performed and ranked in the top ten among all hospitals in the city, including public hospitals. Additionally, DeltaHealth has recently expanded its services to cover thoracic surgery and oncology. This is the first time for Swire Group to become the controlling shareholder of a portfolio company in the medical service sector, which aligns with its strategy of holding and operating healthcare businesses in the long term.

Throughout this transaction, Fangda’s Shanghai and Hong Kong offices worked closely together, leveraging the firm’s integrated strengths to provide Swire Group with efficient and comprehensive transaction services and legal advice. Fangda team is led by partners Norman Zhong, Mark Lehmkuhler, Helen Fan and Eric Yan. Other core team members include Wyatt Zhang, Scheu Joe, Jingyi Li, Jessica Zhuang, Jiali Yang and Tianyu Shen.